Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
261-280 of 936 trials

Advanced Tumor Cancer: ABBV-CLS-484 Treatment

We are studying a new treatment called ABBV-CLS-484 for people with advanced tumor cancer. The trial will explore its effects alone and in combination with other therapies.

Advanced Cancer>2 yearsSafety phase (I)Oncology

Asthma and COPD: GB-0895 Study

We are investigating the safety of a new drug, GB-0895, in patients with mild to moderate asthma and those with COPD. This study aims to understand how well the drug is tolerated in these groups.

Mild to Moderate AsthmaChronic Obstructive Pulmonary Disease (COPD)>2 yearsSafety phase (I)Pulmonology

Systemic Lupus Erythematosus: CABA-201 T Cell Therapy

We are studying a new T cell therapy for people with active systemic lupus erythematosus to see if it is safe and effective. This research aims to understand how it affects disease activity and overall health.

Systemic Lupus Erythematosus>2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyRheumatology

Hepatitis B: TherVacB Vaccine Study

We are testing a new vaccine for adults with hepatitis B to see if it is safe and how well it boosts the immune response. The study will also check if it helps reduce the virus in the body.

Chronic Hepatitis B6-12 monthsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesHepatologyInfectious Diseases

Chronic Lymphocytic Leukemia: ABBV-453 Study

We are assessing how the oral medication ABBV-453 affects adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. The study focuses on understanding its side effects and how it moves through the body.

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma>2 yearsSafety phase (I)Oncology

MB-CART19.1 for Refractory Systemic Lupus Erythematosus

We are testing a new treatment for patients with systemic lupus erythematosus that has not responded to standard therapies. The goal is to see if this new approach can provide better outcomes.

Systemic Lupus Erythematosus>2 yearsSafety phase (I)Efficacy phase (II)Rheumatology

Prostate Cancer: [225Ac]Ac-PSMA-R2 Treatment Study

We are studying a new treatment for men with advanced prostate cancer to see if it is safe and effective. This trial includes men who have been treated before and those who have not.

Advanced Prostate CancerSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Chronic Myeloid Leukemia: TERN-701 Treatment

We are evaluating a new treatment called TERN-701 for individuals with chronic myeloid leukemia. The study aims to assess its safety and how well it works compared to existing options.

Chronic Myeloid Leukemia>2 yearsSafety phase (I)Oncology

Acute Respiratory Distress Syndrome: PRS CK STORM Treatment

We are testing a new cell therapy to see if it helps patients with acute respiratory distress syndrome caused by viruses like COVID-19 and influenza. The study will evaluate its safety and effectiveness in reducing severe immune responses.

Acute Respiratory Distress Syndrome (ARDS)>2 yearsSafety phase (I)Infectious DiseasesPulmonology

Frontotemporal Dementia: PBFT02 Treatment Study

We are evaluating a new treatment for adults with Frontotemporal Dementia linked to GRN or C9orf72 mutations. The study aims to understand its safety and how well it works in this specific group.

Frontotemporal DementiaSafety phase (I)Efficacy phase (II)Neurology

B-Cell Non-Hodgkin Lymphoma: Glofitamab Treatment

We are studying a new treatment using Glofitamab after Obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Our goal is to evaluate its safety and effectiveness compared to standard treatments.

B-cell Non-Hodgkin's Lymphoma Refractory>2 yearsSafety phase (I)HematologyOncology

Nasal Treatment: HY-133 Bacteriophage Endolysin

We are testing a new nasal treatment to see if it is safe and effective for patients. This study also explores how it affects the nasal microbiome.

Nasal Colonization with MSSA1-2 yearsSafety phase (I)Infectious DiseasesOtolaryngology

Multiple Myeloma: BGB-11417 Treatment Study

We are investigating the safety and effectiveness of BGB-11417 alone and with other medications for patients with relapsed or refractory multiple myeloma. This study aims to find the best treatment options for those with a specific genetic marker.

Relapsed or Refractory Multiple Myeloma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Advanced Cancers: MAQ-001 Treatment Study

We are evaluating the safety of MAQ-001, both alone and with other treatments, for patients with advanced cancers. This study aims to understand how well it works in this patient group.

Advanced Cancers Treated with Immune Checkpoint Blockade>2 yearsSafety phase (I)Oncology

Linvoseltamab for Relapsed or Refractory AL Amyloidosis

We are studying whether linvoseltamab is safe and effective for adults with relapsed or refractory systemic light chain amyloidosis. The trial will help us understand its impact on blood response and overall health.

Relapsed or Refractory Systemic Light Chain Amyloidosis>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHematologyInternal Medicine

Multiple Sclerosis: CD19-targeted CAR T Cell Therapy

We are testing a new CAR T cell treatment for people with relapsing or progressive multiple sclerosis. The goal is to see if it can improve symptoms and overall health.

Relapsing Multiple SclerosisProgressive Multiple SclerosisMyasthenia GravisSafety phase (I)Internal MedicineNeurology

Triple-Negative Breast Cancer: 68Ga-FAPI-46 PET/CT Imaging Study

We are investigating whether a new imaging method can predict how well early-stage high-risk triple-negative breast cancer patients respond to chemotherapy and immunotherapy. This may help tailor treatments more effectively.

Breast Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncologyOtolaryngology

Multiple Sclerosis: Ifenprodil Study

We are investigating whether Ifenprodil can help repair nerve damage in people with Multiple Sclerosis. This study aims to see if it may improve symptoms and overall function.

Multiple Sclerosis>2 yearsSafety phase (I)Efficacy phase (II)Neurology

Multiple Myeloma: Etentamig Injection Study

We are investigating the safety and effectiveness of a new injectable treatment for patients with relapsed or refractory Multiple Myeloma. This study aims to understand how well it works compared to existing therapies.

Relapsed or Refractory Multiple Myeloma>2 yearsSafety phase (I)Oncology

Advanced Solid Tumors: First-in-Human Study of DS-3939a

We are testing a new treatment called DS-3939a to see if it is safe and effective for people with advanced solid tumors. This study aims to understand how well it works and its effects on tumor tissue.

Metastatic Solid TumorAdvanced Solid TumorSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology